Novartis India financials

·Pharma & HealthChart ›

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast closeFY25Mar 2025FY24Mar 2024FY23Mar 2023
52.152.145.019.4
0.00.01.4—
356356335379
—+6.3%−11.5%—
91.491.465.365.1
25.7%25.7%19.5%17.2%
89.289.262.759.0
10110185.2103
28.3%28.3%25.4%27.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

NOVARTIND₹1,821.40

Novartis India Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLPARNAXLABSGRLSHUKRAPHARSUNLOC
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Current
last close
- Cash, Equiv & ST Investments19.445.052.152.1
+ Total Debt—1.40.00.0
Revenue378.7335.1356.3356.3
Growth %, YoY—-11.5+6.3—
EBITDA65.165.391.491.4
Margin %17.1819.4825.6625.66
EBIT59.062.789.289.2
Net Income103.485.2100.9100.9
Margin %27.2925.4228.3228.32
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.

Novartis India financials and key ratios

Figures from the company's filings with NSE

In FY25 its consolidated net profit was ₹101 crore on revenue of ₹356 crore. It had no borrowings on 31 March 2025.

Latest balance sheet
31 March 2025

Novartis India at a glance · consolidated

Debt to equity
0.00net cash ₹52.1 Cr
Net worth
₹785 Cr31 March 2025

Questions

Is Novartis India debt free?

Yes. Novartis India had no borrowings on 31 March 2025 (consolidated balance sheet), and it held ₹52.1 crore of cash, bank balances and current investments.

What is the Novartis India debt to equity ratio?

Novartis India's debt-to-equity ratio was 0.00 on 31 March 2025: no borrowings against total equity of ₹785 crore.

What is the Novartis India net worth?

Novartis India's net worth — shareholders' equity in its consolidated balance sheet — was ₹785 crore on 31 March 2025.

What is the Novartis India revenue and profit in FY25?

In FY25 (April 2024–March 2025), Novartis India's consolidated net profit was ₹101 crore, up 18.4% from ₹85.2 crore in FY24, on revenue from operations of ₹356 crore (up 6.3%). Over three years, from FY21, net profit was up 382.8%.

Where do these Novartis India figures come from?

From Novartis India's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.